To address the lack of reliable biomarkers in cancer immunotherapy and the inadequacy of current screening methods for these biomarkers, we proposed CD103 ImmunoPET of tissue-resident memory T cell as a potential method for determining TILs load and response to ICIs. Here, ITGAE is linked to cancer.